Written question asked by Baroness Debbonaire (Labour) on Tuesday, 1 November 2016, in the House of Commons. It was due for an answer on Friday, 4 November 2016 (named day). It was answered by Baroness Blackwood of North Oxford (Conservative) on Friday, 4 November 2016 on behalf of the Department of Health.
Nivolumab
- Question
-
To ask the Secretary of State for Health, pursuant to the Answer of 27 June 2014 to Question 40281, on what date he expects NICE to publish the results of the consultation on the guidance on the use of nivolumab for the treatment of lung cancer.
- Answer
-
The National Institute for Health and Care Excellence (NICE) is currently carrying out two separate technology appraisals of nivolumab (Opdivo) for previously treated locally advanced or metastatic non-squamous non-small cell lung cancer and previously treated locally advanced or metastatic squamous non-small-cell lung cancer after prior chemotherapy in adults.
NICE is currently consulting on draft guidance for both appraisals and the closing date for comments is 4 November 2016. Subsequent timescales for guidance development are yet to be confirmed by NICE. NICE will publish comments received in response to the consultation and its responses alongside the next iteration of its draft guidance.
Secondary information
- Type
- Written question
- Reference
- 51363
- Session
- 2016-17
- Related items
- Subjects
- Medical treatments Lung cancer Nivolumab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2020-01-07 12:49:20 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/51363
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/51363
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/51363